| Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials PW Noble, C Albera, WZ Bradford, U Costabel, MK Glassberg, ... The Lancet 377 (9779), 1760-1769, 2011 | 2410 | 2011 |
| Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement RP Baughman, M Drent, M Kavuru, MA Judson, U Costabel, R du Bois, ... American journal of respiratory and critical care medicine 174 (7), 795-802, 2006 | 793 | 2006 |
| Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial TE King, C Albera, WZ Bradford, U Costabel, P Hormel, L Lancaster, ... The Lancet 374 (9685), 222-228, 2009 | 668 | 2009 |
| Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference RM Du Bois, D Weycker, C Albera, WZ Bradford, U Costabel, A Kartashov, ... American journal of respiratory and critical care medicine 184 (12), 1382-1389, 2011 | 566 | 2011 |
| Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference RM Bois, D Weycker, C Albera, WZ Bradford, U Costabel, A Kartashov, ... American journal of respiratory and critical care medicine 183 (9), 1231-1237, 2011 | 562 | 2011 |
| Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials PW Noble, C Albera, WZ Bradford, U Costabel, RM Du Bois, EA Fagan, ... European Respiratory Journal 47 (1), 243-253, 2015 | 507 | 2015 |
| Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis RM du Bois, D Weycker, C Albera, WZ Bradford, U Costabel, A Kartashov, ... American journal of respiratory and critical care medicine 184 (4), 459-466, 2011 | 505 | 2011 |
| Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis SD Nathan, C Albera, WZ Bradford, U Costabel, I Glaspole, MK Glassberg, ... The Lancet Respiratory Medicine 5 (1), 33-41, 2017 | 334 | 2017 |
| An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial D Khanna, C Albera, A Fischer, N Khalidi, G Raghu, L Chung, D Chen, ... The Journal of rheumatology 43 (9), 1672-1679, 2016 | 287 | 2016 |
| Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial L Richeldi, ERF Pérez, U Costabel, C Albera, DJ Lederer, KR Flaherty, ... The Lancet Respiratory Medicine 8 (1), 25-33, 2020 | 283 | 2020 |
| 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis RM du Bois, C Albera, WZ Bradford, U Costabel, JA Leff, PW Noble, ... European Respiratory Journal 43 (5), 1421-1429, 2014 | 253 | 2014 |
| Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis LH Lancaster, JA de Andrade, JD Zibrak, ML Padilla, C Albera, ... European respiratory review 26 (146), 2017 | 252 | 2017 |
| Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis MA Judson, RP Baughman, U Costabel, M Drent, KF Gibson, G Raghu, ... European Respiratory Journal 44 (5), 1296-1307, 2014 | 213 | 2014 |
| Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with … SD Nathan, C Albera, WZ Bradford, U Costabel, RM Du Bois, EA Fagan, ... Thorax 71 (5), 429-435, 2016 | 212 | 2016 |
| Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function C Albera, U Costabel, EA Fagan, MK Glassberg, E Gorina, L Lancaster, ... European Respiratory Journal 48 (3), 843-851, 2016 | 201 | 2016 |
| All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials TE King Jr, C Albera, WZ Bradford, U Costabel, RM Du Bois, JA Leff, ... American journal of respiratory and critical care medicine 189 (7), 825-831, 2014 | 172 | 2014 |
| An open-label study of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (RECAP) U Costabel, C Albera, LH Lancaster, CY Lin, P Hormel, HN Hulter, ... Respiration 94 (5), 408-415, 2017 | 156 | 2017 |
| Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials L Lancaster, C Albera, WZ Bradford, U Costabel, RM Du Bois, EA Fagan, ... BMJ open respiratory research 3 (1), e000105, 2016 | 141 | 2016 |
| Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis KR Flaherty, CD Fell, JT Huggins, H Nunes, R Sussman, C Valenzuela, ... European Respiratory Journal 52 (2), 2018 | 140 | 2018 |
| Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial J Behr, E Bendstrup, B Crestani, A Günther, H Olschewski, CM Sköld, ... The Lancet Respiratory Medicine 4 (6), 445-453, 2016 | 140 | 2016 |
